All In Biotech

Drug Trial Radar · NCT04740307

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

A Phase 2, Multicenter, Clinical Study to Evaluate the Safety and Efficacy of MK-1308A (Coformulated MK-1308/MK-3475) in Combination With Lenvatinib (E7080/MK-7902) in First-line Therapy of Participants With Advanced Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

116

Actual

Start

Mar 16, 2021

Primary completion

Jul 29, 2025

Study completion Jul 29, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Feb 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting. No hypothesis testing will be performed.

Conditions

  • Advanced Hepatocellular Carcinoma

Interventions

  • Pembrolizumab/QuavonlimabBiological

    Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.

  • LenvatinibDrug

    Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).

  • PembrolizumabBiological

    Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With a Dose-Limiting Toxicity (DLT) in the Safety Lead-in PhaseTime frame: 3 weeks
  2. Number of Participants With ≥1 Adverse Event (AE)Time frame: Up to approximately 44 months
  3. Number of Participants With ≥1 Serious Adverse Event (SAE)Time frame: Up to approximately 44 months
  4. Number of Participants With ≥1 Immune-related AE (irAE)Time frame: Up to approximately 44 months
  5. Number of Participants With ≥1 Hepatic AETime frame: Up to approximately 44 months
  6. Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to approximately 40 months
  7. Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 51 months

Locations

40 sites in 9 countries. Site status is shown where the registry gives one.

  • City of Hope Comprehensive Cancer Center ( Site 0002)

    Duarte, California

  • Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013)

    Baltimore, Maryland

  • Icahn School of Medicine at Mount Sinai ( Site 0009)

    New York, New York

  • Oregon Health and Science University ( Site 0006)

    Portland, Oregon

  • Charleston Oncology ( Site 0003)

    Charleston, South Carolina

  • Blue Ridge Cancer Care ( Site 0008)

    Roanoke, Virginia

  • Virginia Mason Medical Center ( Site 0004)

    Seattle, Washington

  • Anhui Provincial Hospital ( Site 0113)

    Hefei, Anhui, China

  • Beijing Cancer hospital-Department of Hepato-Pancreato-Biliary Surgery II ( Site 0107)

    Beijing, Beijing Municipality, China

  • Fuzhou General hospital of Nanjing Military Command-Oncology Department ( Site 0105)

    Fuzhou, Fujian, China

  • Southern Medical University Nanfang Hospital-Liver Cancer Department ( Site 0106)

    Guangzhou, Guangdong, China

  • Wuhan Union Hospital Cancer Center ( Site 0108)

    Wuhan, Hubei, China

  • Hunan Cancer Hospital-intervention department ( Site 0109)

    Changsha, Hunan, China

  • The First Affiliated Hospital of Xian Jiaotong University ward1 depattment of medical oncology ( Sit

    Xi'an, Shaanxi, China

  • Zhongshan Hospital,Fudan University ( Site 0103)

    Shanghai, Shanghai Municipality, China

  • Huashan Hospital Affiliated Fudan University-Surgery Department ( Site 0118)

    Shanghai, Shanghai Municipality, China

  • Ospedale San Raffaele-Oncologia Medica ( Site 0227)

    Milan, Italy

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-Department of Abdominal Oncology ( Site 0230)

    Naples, Italy

  • Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0231)

    Rozzano, Milano, Italy

  • Hiroshima University Hospital ( Site 0156)

    Hiroshima, Japan

  • National Cancer Center Hospital East ( Site 0153)

    Kashiwa, Chiba, Japan

  • Toranomon Hospital Kajigaya ( Site 0154)

    Kawasaki, Kanagawa, Japan

  • Kindai University Hospital- Osakasayama Campus-Department of Gastroenterology and Hepatology ( Site

    Sayama, Osaka, Japan

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Onkologii i Radioterapii ( Site

    Warsaw, Masovian Voivodeship, Poland

  • Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu ( Site 0249)

    Przemyśl, Podkarpackie Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0247)

    Gdansk, Pomeranian Voivodeship, Poland

  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0246)

    Koszalin, West Pomeranian Voivodeship, Poland

  • Asan Medical Center ( Site 0289)

    Seoul, South Korea

  • Seoul National University Bundang Hospital-Medical Oncology ( Site 0290)

    Seongnam, Kyonggi-do, South Korea

  • Samsung Medical Center ( Site 0288)

    Seoul, Kyonggi-do, South Korea

  • Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 0310)

    Barcelona, Spain

  • Hospital Universitario Central de Asturias-Hepatology ( Site 0309)

    Oviedo, Principality of Asturias, Spain

  • Inselspital Bern-Universitätsklinik für Viszerale Chirurgie und Medizin ( Site 0331)

    Bern, Switzerland

  • Hôpitaux Universitaires de Genève (HUG) ( Site 0335)

    Geneva, Canton of Geneva, Switzerland

  • Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 0334)

    Sankt Gallen, Canton of St. Gallen, Switzerland

  • CHUV (centre hospitalier universitaire vaudois) ( Site 0333)

    Lausanne, Canton of Vaud, Switzerland

  • UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 0332)

    Zurich, Canton of Zurich, Switzerland

  • NATIONAL CHENG-KUNG UNI. HOSP.-Clinical Trial Research Team of Liver Diseases ( Site 0354)

    Tainan, Taiwan

  • National Taiwan University Hospital-Oncology ( Site 0351)

    Taipei, Taiwan

  • Taipei Veterans General Hospital-Division of Gastroenterology & Hepatology, Department of Medicine (

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.